Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jul 2019 to Jul 2024
GammaCan International (OTCBB: GCAN) today announced the
appointment of Richard Spritz, M.D. to the Company's Scientific
Advisory Board.
Bringing over thirty years of medical and scientific acumen to
GammaCan, and specifically to the Company's mission of bringing
VitiGam to the clinic, Dr. Spritz is a member of the Medical Advisory
Board of Vitiligo Support International and a Council Member of
PanAmerican Pigment Cell Society.
"We are extremely pleased that Richard has joined our Scientific
Advisory Board and are honored by his participation. Richard's work on
the identification and cloning of genes involved in the pathogenesis
vitiligo is groundbreaking and undoubtedly will lead to new insights
into this and other immune-mediated disorders. We both recognized the
connection between our respective research efforts, and the entire
Team at GammaCan is exited to work with Richard as we develop VitiGam
to treat stage III and IV melanoma," stated Patrick Schnegelsberg,
CEO.
Dr. Spritz is presently Director Human Medical Genetics Program
and Professor of Pediatrics, Biochemistry and Molecular Genetics at
the University of Colorado Health Science Center. Prior to his tenure
at the University of Colorado, Dr. Spritz served as Assistant and
Associate Professor of Medical Genetics and Pediatrics at the
University of Wisconsin. Among his numerous accomplishments, Dr.
Spritz sits on the Medical Advisory Board of Vitiligo Support
International, is a member of The Council, PanAmerican Pigment Cell
Society, Chaired a number of NIH Committees, and has for many years
served on National Research Advisory Committees for the March of Dimes
Birth Defects Foundation. He has been published over 170 peer-reviewed
papers and receives ongoing research support from the NIH,
specifically in the genetics of human pigmentation and autoimmune
disorders. Richard Spritz holds an M.D. from Pennsylvania State
University and was a Fellow in Human Genetics at the Yale University
School of Medicine.
"I am delighted to be associated with GammaCan, and look forward
to contributing to the company's efforts, to develop VitiGam. I
believe this has the potential to be an important therapeutic to help
patients suffering from advanced melanoma," said Spritz.
About VitiGam:
VitiGam is GammaCan's second generation intravenous IgG-based
product and a first-in-class anti-cancer immunotherapy. GammaCan plans
on having VitiGam to enter phase I/II testing under a US IND in the
near future after it recently held a pre-IND meeting with the FDA.
VitiGam is being designed to target metastatic melanoma patients with
Stage III and IV melanoma. VitiGam is an IgG product that is different
from standard IgGs: It is manufactured from the plasma of donors with
vitiligo, a benign autoimmune skin condition affecting up to 2% of the
general population. GammaCan scientists have shown that this
"enriched" vitiligo IgG (VitiGam) contains potent anti-melanoma
activity in both in vitro and mouse xenograft melanoma models. Thus,
GammaCan expects VitiGam to provide (1) anti-melanoma activity
directed specifically against malignant melanoma cells and (2)
non-specific anti-cancer activity - as is the case with IgG in
general.
About GammaCan:
GammaCan is a biopharmaceutical company focused on clinical-phase
development and commercialization. GammaCan's initial therapy under
development is a first-in-class anti-cancer immunotherapy aimed at
preventing metastasis (the spread of cancer to other parts of the
body) of a variety of cancers. GammaCan's first generation product
(GCAN101) is currently completing phase II - clinical trials.
For more information about GammaCan visit www.GammaCan.com or call
the company's headquarters in Kiryat Ono, Israel at +972 (03) 738-2616
or toll free 1-866-308-0396 (from North America).
Safe Harbor Statement:
Statements in this document that are not purely historical are
forward-looking statements. Forward-looking statements in this release
include statements regarding the commercialization of an anti-cancer
immunotherapy and the Company developing the boosting of cancer
patients' immune systems with IVIg into an effective treatment. Actual
outcomes and the Company's actual results could differ materially from
those in such forward-looking statements. Factors that could cause
actual results to differ materially include risks and uncertainties
such as the inability to finance the planned development of the
technology, unforeseen technical difficulties in developing the
technology, the inability to obtain regulatory approval for human use,
competitors' therapies proving more effective, cheaper or otherwise
preferable for consumers, inability to market the product we produce,
among other factors, all of which could among other things, delay or
prevent product release or cause our company to fail. For further risk
factors see the risk factors associated with other early state medical
research and development companies filed with the SEC on Edgar.